Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 871-877

  Schutz, Fabio A B ^a,c   Je, Youjin ^b   Richards, Christopher J ^a   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Hospital Sao Jose and Beneficencia Portuguesa de Sao Paulo   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; DACARBAZINE; INTERFERON; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; HUMAN; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; INDOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES;

EID: 84858848994     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.1195     Document Type: Article

References (45)

1. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008
2. Cook KM, Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 60:222-243, 2010
3. Printz C: Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 115:4646, 2009
4. Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cell cancer global evaluation trial. J Clin Oncol 27:3312-3318, 2009
5. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
6. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
7. Coultas L, Chawengsaksophak K, Rossant J, et al: Endothelial cells and VEGF in vascular development. Nature 438:937-945, 2005 (Pubitemid 43093959)
8. Khurana R, Simons M, Martin JF, et al: Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation 112:1813-1824, 2005 (Pubitemid 41368158)
9. Zimmerman MA, Selzman CH, Harken AH: Surgical implications of therapeutic angiogenesis. Surgery 125:243-249, 1999 (Pubitemid 29168809)
10. Choueiri TK, Schutz FA, Je Y, et al: Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 28:2280-2285, 2010
11. Chu D, Lacouture ME, Fillos T, et al: Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 47:176-186, 2008
12. Chu D, Lacouture ME, Weiner E, et al: Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis. Clin Genitourin Cancer 7:11-19, 2009
13. Ewer MS, Suter TM, Lenihan DJ, et al: Cardiovascular adverse events (CV-AES) in a pooled analysis of 1090 patients (PT) from phase 3 suntinib (SU) trials. 35th European Society for Medical Oncology. Milan, Italy, October 8-12, 2010 (abstr 506P)
14. Hutson TE, Procopio G, Escudier B, et al: Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos). J Clin Oncol 28:370s, 2010 (suppl; abstr 4614)
15. Je Y, Schutz FA, Choueiri TK: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974, 2009
16. Kerkela R, Woulfe KC, Durand JB, et al: Sunitinib-induced cardiotoxicity is mediated by offtarget inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15-25, 2009
17. Wu S, Chen JJ, Kudelka A, et al: Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9:117-123, 2008
18. Hernon M, Hoyert DL, Murphy SL, et al: Deaths: Final data for 2006. Natl Vital Stat Rep 57:1-134, 2009
19. Seruga B, Sterling L, Wang L, et al: Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29:174-186, 2010
20. Ranpura V, Hapani S, Wu S: Treatmentrelated mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
21. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996 (Pubitemid 26120810)
22. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). ttp://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
23. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. J Clin Epidemiol 62:1006-1012, 2009
24. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003 (Pubitemid 37088507)
25. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986 (Pubitemid 17189972)
26. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
27. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997 (Pubitemid 27387172)
28. Wildiers H, Fontaine C, Vuylsteke P, et al: Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 123:463-469, 2010
29. Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304:2154-2160, 2010
30. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289, 2009
31. Hoffmann K, Glimm H, Radeleff B, et al: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349, 2008
32. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
33. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
34. Hauschild A, Agarwala SS, Trefzer U, et al: Results of a phase III, randomized, placebocontrolled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830, 2009
35. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
36. McDermott DF, Sosman JA, Gonzalex R, et al: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group. J Clin Oncol 26:2178-2185, 2008
37. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
38. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
39. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
40. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
41. Ricciardi S, Tomao S, de Marinis F, et al: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28-35, 2009
42. Choueiri TK, Mayer EL, Je Y, et al: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632-638, 2011
43. Schutz FA, Je Y, Azzi GR, et al: Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22:1404-1412, 2011
44. Deuse T, Peter C, Fedak PW, et al: Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 120:S247-S254, 2009
45. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008 (Pubitemid 351397066)